March 9, Everest Medicines (HKG: 1952) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by…
Browsing: Everest Medicines Limited
Everest Medicines today announced that China’s National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment…
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization…
Everest Medicines (HKG: 1952) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session…
Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (Everest Medicines China), has…
Everest Medicines (HKG:1952) today announced that it has acquired an exclusive license with Visara, Inc. (Visara), a subsidiary of NovaBridge…
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of…
On August 29, Everest Medicines (HKG: 1952) announced its interim results for the six months ended June 30, 2025. The…
Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults…
Everest Medicines (HKG: 1952.HK, Everest) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New…
Everest Medicines (HKG: 1952) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R).…
Everest Medicines (HKG: 1952) today announced that the supplemental application for the production expansion of NEFECON® has been officially approved…
Everest Medicines (HKG: 1952) today announced a strategic equity investment in I-Mab (NASDAQ: IMAB), under which Everest will invest US$30.9…
Everest Medicines (HKG: 1952) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from…
Everest Medicines (HKG 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization…
– Officially Benefiting Mainland China Patients Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery,…
Officially Beginning to Benefit Asian Patients Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the…
Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical…
Everest Medicines (HKG: 1952, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization…